LSN2463359 is primarily used in pharmaceutical research as a potent and selective inhibitor of the p38α mitogen-activated protein kinase (MAPK). This enzyme is involved in inflammatory pathways, making LSN2463359 a valuable tool compound in studying conditions driven by chronic inflammation, such as rheumatoid arthritis, inflammatory bowel disease, and certain neurodegenerative disorders. Due to its high selectivity, it helps researchers dissect the specific role of p38α signaling without significant off-target effects. It is commonly applied in cellular and in vivo models to evaluate the therapeutic potential of p38 inhibition and to support target validation during early drug discovery. Its use is largely confined to preclinical research, aiding in the development of new anti-inflammatory and immunomodulatory agents.